Constitutional methylation of \textit{BRCA1} gene and breast cancer risk

K. Prajzendanc\textsuperscript{1}, P. Domagała\textsuperscript{2}, J. Ryś\textsuperscript{3}, T. Huzarski\textsuperscript{1}, M. Szwiec\textsuperscript{4,5}, J. Tomiczek-Szwiec\textsuperscript{5,6}, W. Redelbach\textsuperscript{5,7}, A. Sejda\textsuperscript{8}, J. Gronwald\textsuperscript{1}, L. Fudali\textsuperscript{9}, R. Wiśniowski\textsuperscript{10}, A. Łukomska\textsuperscript{1}, K. Białkowska\textsuperscript{1}, G. Sukiennicki\textsuperscript{1}, T. K. Wojdacz\textsuperscript{11}, J. Lubiński\textsuperscript{1,12}, A. Jakubowska\textsuperscript{1,13}

\textsuperscript{1} Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
\textsuperscript{2} Department of Pathology, Pomeranian Medical University, Szczecin, Poland
\textsuperscript{3} Department of Tumor Pathology, Maria Skłodowska-Curie Memorial Centre and Institute of Oncology, Cracow, Poland
\textsuperscript{4} Department of Clinical Oncology, University Hospital in Zielona Gora, Poland
\textsuperscript{5} Faculty of Natural Sciences and Technology University of Opole, Poland
\textsuperscript{6} Department of Oncological Gynecology, Oncology Center in Opole, Opole, Poland
\textsuperscript{7} Oncology Surgery Department, Oncology Center in Opole, Opole, Poland
\textsuperscript{8} Department of Pathology, Provincial Specialist Hospital, Olsztyn, Poland
\textsuperscript{9} Clinical Department of Pathology, Frederick Chopin Clinical Provincial Hospital No 1, Rzeszow, Poland
\textsuperscript{10} Department of Clinical Oncology, Regional Oncology Center, Bielsko-Biala, Poland
\textsuperscript{11} Aarhus Institute of Advanced Studies, University of Aarhus, Aarhus, Denmark
\textsuperscript{12} Read-Gene S.A., Grzepnica, Polska
\textsuperscript{13} Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland

Methylation of CpG islands in promoter region of genes is an epigenetic modification that causes silencing of genes and might be associated with cancer risk if it is present in peripheral blood. It has been suggested that constitutional methylation of \textit{BRCA1} promoter correlates with breast cancer risk, especially with triple-negative tumors.

In this study we evaluated an association of \textit{BRCA1} methylation in peripheral blood with breast cancer risk and assessed correlation with clinical features of tumors. We examined three groups of women: 504 triple-negative breast cancer cases, 438 non-TNBC cases and 500 healthy controls. All women were negative for 13 common Polish \textit{BRCA1} germline mutations. Moreover, 274 FFPE tumor tissues were tested to estimate association between constitutional and somatic \textit{BRCA1} promoter methylation. Methylation status was assessed using methylation-sensitive high-resolution melting (MS-HRM). Additionally, we genotyped variant c.-107A>T in \textit{BRCA1} gene to assess its potential correlation with \textit{BRCA1} methylation.

The results show that \textit{BRCA1} methylation detected in peripheral blood is significantly associated with the risk of TNBC (OR 5.25, p < 0.001) and correlates with methylation in paired tumors. The variant c.-107A>T was not detected in tested women from Polish population.

The study was supported by the National Science Centre (NCN) grant 2014/15/B/NZ1/03386.